As Streptococcus A cases continue to be prevalent, a new nasal vaccine could provide long-term protection from the deadly bacteria. The development of a Strep A vaccine which is currently in Phase 1 clinical trials in Canada and quickly advancing to Phase 2 efficacy trials.
Click here for original story, Vaccine via the nasal passage could be the new line of defence against Strep A
Source: ScienceDaily